Jeffrey D. Wager, M.D.

Jeffrey D. Wager, M.D. has a diverse work experience in the life science and pharmaceutical industries. Jeffrey D. is currently serving as the Chair & CEO at Spexis AG, a Swiss rare disease and oncology company focused on chronic respiratory diseases. Prior to this, they were the Co-Founder and Executive Chairman at Proterris, Inc., a carbon monoxide therapeutics company.

Dr. Wager also founded and managed Apeiron Partners LLC, where they provided leadership and expertise in company formation, CEO leadership, venture capital, investment banking, and corporate development. Jeffrey D. has been involved in the formation and growth of over 40 companies and has successfully completed six corporate spin-outs.

Before founding Apeiron Partners, Dr. Wager co-founded and served as the Chairman & CEO of EnBiotix, Inc., an engineered antibiotics company. Jeffrey D. also co-founded Artisan Pharma, Inc., where they held multiple roles including President & CEO, and served on the Board of Directors.

Dr. Wager started their career as a Senior Associate at Medical Science Partners and later worked as the Executive Director of Business Development in the Life Sciences Group at Kasho Company Limited.

Overall, Dr. Jeffrey D. Wager, M.D. has a wealth of experience and expertise in various domains of the life science and biopharmaceutical industries, showcasing their strong leadership and strategic abilities.

Jeffrey D. Wager, M.D. obtained their M.D. degree from Rush Medical College of Rush University Medical Center, graduating in 1988. Following their medical training, they pursued further education and earned an MBA degree from The University of Chicago Booth School of Business between 1996 and 1998.